U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -1.53 (-2.86%)
     
  • Gold

    1,827.70
    -23.70 (-1.28%)
     
  • Silver

    24.83
    -0.97 (-3.77%)
     
  • EUR/USD

    1.2085
    -0.0079 (-0.6526%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3583
    -0.0057 (-0.4143%)
     
  • USD/JPY

    103.8710
    +0.0290 (+0.0279%)
     
  • BTC-USD

    37,473.50
    +455.22 (+1.23%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.12 (-0.62%)
     

NIH pauses enrollment of critically ill patients in trials testing blood thinners against COVID-19

·1 min read

Dec 22 (Reuters) - The U.S. National Institutes of Health (NIH) said on Tuesday it had paused enrollment of critically ill COVID-19 patients requiring intensive care unit support in its trials testing blood thinners against the respiratory illness.

Enrollment continues for moderately ill hospitalized COVID-19 patients, the agency said.

All trial sites have paused enrollment in this group of most critically ill hospitalized COVID-19 patients, based on deliberations of data review boards consisting of independent experts, the NIH said in a statement. https://www.nih.gov/news-events/news-releases/nih-activ-trial-blood-thinners-pauses-enrollment-critically-ill-covid-19-patients

Increased bleeding is a known complication of full-dose blood thinners and a potential for harm in this group could not be overruled, the agency said.

The NIH in September announced the launch of two of the three late-stage clinical trials to test the effectiveness and safety of different types of blood thinners in treating COVID-19 among adults.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)